In Cell Art

In-Cell-Art, is a biopharmaceutical company specializing in the preclinical and pharmaceutical development of solutions (DNA/RNA based vaccines or therapeutics) treating acquired or inherited diseases using patented bioinspired synthetic delivery systems (named Nanotaxi®) consisting of different chemical families (lipids, polymers). Its founder and research team, which includes a Nobel Laureate, have developed this unique intellectual property expertise and know-how based on 20 years of research in the field of supramolecular nucleic acids transfection agents. The vaccines and therapeutics developed by In-Cell-Art have been validated by numerous studies using infectious disease models (HIV, Flu, Dengue, dust mite, mycobacterium abscessus), therapeutic cancer models (melanoma, liver, breast and cervical cancers) and therapeutic models (muscular dystrophy, anemia in kidney failure) In-Cell-Art has recently advanced vaccines into regulatory preclinical studies for human trials and shown promising safety and immunogenicity profiles. In-Cell-Art's people have international qualifications, experience and expertise in the fields of supramolecular chemistry, physico-chemical characterization and preclinical pharmaceutical development. It includes a highly experienced Scientific Advisory Board of recognized experts comprising Jean Marie Lehn (Nobel Laureate), Bruno Pitard, CSO of In-Cell-Art, Didier Roux, VP R&D of Saint Gobain, Luc Aujame former Senior Director in External R&D at Sanofi Pasteur and Georges-Bernard Guillou, MD, former director of Pharmaceutical R&D and Scientific Affairs & Licensing at Laboratoires Expanscience. In-Cell-Art is based in Nantes (France) and member of Atlanpole Biotherapies cluster of biotechnology companies focusing in the development of biotherapeutics.